Richard Ding, CEO
Richard Ding has over 17 years of management experience in the pharmaceutical and diagnostics industry. As a member of the team at Myriad Genetics that cloned BRCA1 gene, Richard Ding made a significant contribution to the development of one of the first molecular genetic tests. Prior to becoming CEO of bioTheranostics, Richard Ding had taken various cross-functional positions at Eli Lilly and Company. In addition to his current role at bioTheranostics, Richard serves on the Executive Committee at bioMérieux as head of Strategy and Business Development. Richard holds an MBA from the University of Utah and received his undergraduate education and scientific training at Fudan University, China.
Mary Jo Mullen, Chief Commercial Officer
Mary Jo Mullen brings bioTheranostics more than 22 years of experience in clinical testing, medical device sales and sales leadership. Prior to joining bioTheranostics, she held senior-level sales management positions at LabCorp through its acquisition of Genzyme Genetics, a premier reproductive genetics and oncology laboratory. She managed international business, strategic accounts, and directed training for both the genetics and oncology divisions. She has also led sales teams and managed care sales at Phillips Medical Systems and Matria Healthcare. Mullen earned her BSN from the University of Missouri-Columbia. As chief commercial officer, Mullen leads the company’s sales, marketing and client services teams and identifies new opportunities to showcase bioTheranostics as the leading provider of solutions for metastatic cancer.
Isaac Bright, M.D., Vice President Corporate Development
Dr. Isaac Bright comes to bioTheranostics with a decade of progressive experience in business and strategic development in genomic and molecular diagnostics and the medical device industry. As vice president of corporate development, he plays a key role in bioTheranostics’ business development and corporate strategy efforts, enhancing and providing guidance on current business initiatives, as well as developing and implementing long-range company goals. Dr. Bright joined bioTheranostics from QuantaLife, a life sciences company that provides advanced genetic analysis systems for research. He led the sale of QuantaLife in 2011 to Bio-Rad Laboratories. Previously, Dr. Bright held corporate development and business development leadership roles with Medtronic and an investment banking position with CIBC World Markets. He earned his medical degree from the Stanford University School of Medicine and was a Howard E. Mitchell Fellow at The Wharton School of the University of Pennsylvania.
Michael C. Dugan, M.D., Chief Medical Officer
Michael Dugan has more than 15 years of experience in molecular diagnostics and pathology. As chief medical officer, he is responsible for delivering high-quality testing services in partnership with bioTheranostics’ commercial team. Prior to joining bioTheranostics, Dr. Dugan was vice president and chief medical officer at Roche Molecular Systems, Inc., and held senior pathology/laboratory and management positions at Genzyme Genetics and Specialty Laboratories, Inc. He also was chief of pathology and medical director of clinical laboratories at Santa Monica UCLA Medical Center, as well as a staff pathologist for Affiliated Pathologists Medical Group. He also has served as assistant professor of pathology at both UCLA and Wayne State University School of Medicine. Dr. Dugan earned his bachelor’s degree in biology from the University of Notre Dame and his medical degree from the University of Arizona College of Medicine. He also received postgraduate training at Yale-New Haven Hospital, Children’s Hospital Los Angeles, and UCLA.
Lale White, Executive Chairman and CEO of Xifin, Inc.
Lale White is founder and CEO of XIFIN, Inc. XIFIN is the innovator and provider of a new accounts receivable and financial management application for the healthcare industry. Ms White is a nationally recognized expert in the field of medical financial management and regulatory compliance. She lectures and consults extensively on these topics to major laboratories and laboratory associations throughout the U.S.A She has over 20 years of successful executive leadership in financial management, information systems development and medical billing with several of the largest independent clinical reference laboratories where she held senior management positions. Prior to founding XIFIN, Ms. White was Vice President of Finance at Laboratory Corporation of America. She was also a principal contributor in working with HCFA and the U.S. Office Of The Inspector General to develop the current OIG Model Compliance Program. Lale holds an MBA degree in Finance from Florida International University.
Brian Armstrong, Chief Financial Officer of bioMérieux Inc.
Brian Armstrong is the Chief Financial Officer for bioMérieux Inc. Based in Durham, North Carolina, he is responsible for all financial aspects of the bioMérieux US operations. Brian has been with bioMérieux for 17 years. Prior to joining bioMérieux, he was Audit Senior Manager with Ernst & Young. He is a CPA and member of AICPA.
Brad Smith, former Vice Chairman of LabCorp
Brad Smith is a former Vice Chairman of LabCorp. He has extensive executive experience in operations, legal and corporate affairs within the diagnostics and clinical laboratory industry. He has also held various positions including Assistant Vice President Law and General Counsel with Roche Biomedical Laboratories.